Zymeworks Inks ~$813M Deal with Roche to Advance ZW209

Shots: Zymeworks has entered into a global license & collaboration agreement with Roche for the research, development & commercialization of a DLL3-targeting T cell engager ZW209   As per the deal, Roche will obtain exclusive global rights to develop & commercialize ZW209, & both companies will jointly conduct the P-Ia monotx. trial of ZW209, with Roche funding the trial & handling subsequent global development & commercialization of ZW209 Zymeworks will receive $55M upfront, $40M upon P-Ib trial initiation, & ~$718M in additional development, commercial and sales-based milestone payments, with tiered high single-digit to mid-teen royalties on future net sales Ref: Zymeworks  |   Image: Zymeworks & Roche  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Zymeworks Inks ~$813M Deal with Roche to Advance ZW209 appeared first on PharmaShots.